Pay in 4 interest-free payments of $31.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC® research and development
InChi: InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H
Vandetanib was approved in 2011
5-Isoquinolinediamine
E-3810 - CAS# 1058137-23-7 04995274 Functionalized von-Hippel-Lindau (VHL) protein ligandLucitanib , also known as E 3810 and AL3810, is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. VEGFR FGFR dual kinase inhibitor E 3810 inhibits VEGFR 1, 2, 3 and FGFR 1, 2 kinases in the nM range, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both
US$ 200.00
US$ 124.81
US$ 26.22
US$ 399.50